Event Date/Time: Nov 05, 2012 End Date/Time: Nov 07, 2012
Report as Spam


t is the only meeting specifically designed to provide senior corporate and R&D executives with a strategic-level snapshot of the CNS sector.

The agenda for the 2012 edition will provide invaluable insights into the strategic plays of the major pharma and biotech companies as they wrestle with issues ranging from high level R&D organizational and commercial strategies to more detailed exploration of:

How to accelerate preclinical-clinical translation, and optimize it for later success
Phase II/III clinical trial designs in the neurodegenerative disease space
Opportunities presented by rare CNS diseases and orphan indications
The impact of novel biologic modalities on the CNS field moving forward
Business models and results to date from key pre-competitive CNS biomarker consortia (including an in-depth look at the value of imaging technologies in practical drug development terms)
The latest, most innovative licensing and partnering models being employed within the global CNS therapeutics sector today